The lymphocyte-to-monocyte ratio as a significant inflammatory marker associated with survival of patients with metastatic renal cell carcinoma treated using nivolumab plus ipilimumab therapy-Reference-Cited by-同舟云学术

The lymphocyte-to-monocyte ratio as a significant inflammatory marker associated with survival of patients with metastatic renal cell carcinoma treated using nivolumab plus ipilimumab therapy

Published:2024-05-26 Issue:7 Volume:29 Page:1019-1026
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Numakura Kazuyuki,Sekine Yuya,Osawa Takahiro,Naito Sei,Tokairin Ojiro,Muto Yumina,Sobu Ryuta,Kobayashi Mizuki,Sasagawa Hajime,Yamamoto Ryohei,Nara Taketoshi,Saito Mitsuru,Narita Shintaro,Akashi Hideo,Tsuchiya Norihiko,Shinohara Nobuo,Habuchi Tomonori

Funder

Grant-in-Aid for Scientific Research, Japan

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10147-024-02538-8.pdf

Reference44 articles.

1. Cardenas LM, Ghosh S, Finelli A et al (2023) Trends of utilization of systemic therapies for metastatic renal cell carcinoma in the Canadian health care system. JCO Glob Oncol 9:e2300271

2. Ingels A, Campi R, Capitanio U et al (2022) Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma. Nat Rev Urol 19:391–418

3. Kido K, Hatakeyama S, Numakura K et al (2021) Comparison of nivolumab plus ipilimumab with tyrosine kinase inhibitors as first-line therapies for metastatic renal-cell carcinoma: a multicenter retrospective study. Int J Clin Oncol 26:154–162

4. Motzer RJ, Tannir NM, McDermott DF et al (2018) Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 378:1277–1290

5. Numakura K, Sekine Y, Hatakeyama S et al (2023) Primary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinoma. Cancer Med 12:16837–16845